These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 19934029)

  • 1. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
    Gu J; Noe A; Chandra P; Al-Fayoumi S; Ligueros-Saylan M; Sarangapani R; Maahs S; Ksander G; Rigel DF; Jeng AY; Lin TH; Zheng W; Dole WP
    J Clin Pharmacol; 2010 Apr; 50(4):401-14. PubMed ID: 19934029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
    Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
    Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.
    Gan L; Langenickel T; Petruck J; Kode K; Rajman I; Chandra P; Zhou W; Rebello S; Sunkara G
    J Clin Pharmacol; 2016 Jan; 56(1):78-86. PubMed ID: 26073563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
    Langenickel TH; Tsubouchi C; Ayalasomayajula S; Pal P; Valentin MA; Hinder M; Jhee S; Gevorkyan H; Rajman I
    Br J Clin Pharmacol; 2016 May; 81(5):878-90. PubMed ID: 26663387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
    Akahori M; Ayalasomayajula S; Langenickel T; Pal P; Zhou W; Sunkara G
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):407-416. PubMed ID: 27324506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
.
    Ayalasomayajula S; Langenickel TH; Chandra P; Wolfson ED; Albrecht D; Zhou W; Pal P; Rajman I; Sunkara G
    Int J Clin Pharmacol Ther; 2016 Dec; 54(12):1012-1018. PubMed ID: 27719743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
    Hsiao HL; Langenickel TH; Greeley M; Roberts J; Zhou W; Pal P; Rebello S; Rajman I; Sunkara G
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):407-17. PubMed ID: 27137712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.
    Han Y; Ayalasomayajula S; Pan W; Yang F; Yuan Y; Langenickel T; Hinder M; Kalluri S; Pal P; Sunkara G
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):109-116. PubMed ID: 26961539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects.
    Flarakos J; Du Y; Bedman T; Al-Share Q; Jordaan P; Chandra P; Albrecht D; Wang L; Gu H; Einolf HJ; Huskey SE; Mangold JB
    Xenobiotica; 2016 Nov; 46(11):986-1000. PubMed ID: 26931777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects.
    Ayalasomayajula S; Pan W; Han Y; Yang F; Langenickel T; Pal P; Zhou W; Yuan Y; Rajman I; Sunkara G
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):309-318. PubMed ID: 27245340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LCZ696 : a new paradigm for the treatment of heart failure?
    Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P
    Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
    Langenickel TH; Jordaan P; Petruck J; Kode K; Pal P; Vaidya S; Chandra P; Rajman I
    Eur J Clin Pharmacol; 2016 Aug; 72(8):917-24. PubMed ID: 27083930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
    Ruilope LM; Dukat A; Böhm M; Lacourcière Y; Gong J; Lefkowitz MP
    Lancet; 2010 Apr; 375(9722):1255-66. PubMed ID: 20236700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
    von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
    Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
    Ayalasomayajula SP; Langenickel TH; Jordaan P; Zhou W; Chandra P; Albrecht D; Pal P; Rajman I; Sunkara G
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1065-73. PubMed ID: 27230850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
    Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J
    Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
    Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
    Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
    Gan L; Jiang X; Mendonza A; Swan T; Reynolds C; Nguyen J; Pal P; Neelakantham S; Dahlke M; Langenickel T; Rajman I; Akahori M; Zhou W; Rebello S; Sunkara G
    Clin Pharmacol Drug Dev; 2016 Jan; 5(1):27-39. PubMed ID: 27119576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.